Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection

Vaccine

Volumn 27, Issue 21, 2009, Pages 2884-2890

  Goto, Yasuyuki ^a   Bhatia, Ajay ^a   Raman, Vanitha S ^a   Vidal, Silvia E Z ^a   Bertholet, Sylvie ^a   Coler, Rhea N ^a   Howard, Randall F ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

Leishmaniasis; Sterol 24 c methyltranferase; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 2; LEISHMANIA VACCINE; PHOSPHORYL LIPID A; RECOMBINANT ANTIGEN; STEROL 24 C METHYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG MECHANISM; EMULSION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; SPLEEN CELL; TH1 CELL; TH2 CELL;

ANIMALS; ANTIGENS, PROTOZOAN; CELLS, CULTURED; CRICETINAE; CROSS REACTIONS; EMULSIONS; FEMALE; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; METHYLTRANSFERASES; MICE; TH1 CELLS; TH2 CELLS;

EID: 64449087496     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.079     Document Type: Article

References (33)

1. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174 June (11) (2005) 7160-7171
2. Stager S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 December (12) (2000) 7064-7071
3. Ghosh A., Zhang W.W., and Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20 October (1-2) (2001) 59-66
4. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 63 May (5) (1995) 2062-2069
5. Tewary P., Jain M., Sahani M.H., Saxena S., and Madhubala R. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis 191 June (12) (2005) 2130-2137
6. Aguilar-Be I., da Silva Zardo R., Paraguai de Souza E., Borja-Cabrera G.P., Rosado-Vallado M., Mut-Martin M., et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun 73 February (2) (2005) 812-819
7. Rafati S., Zahedifard F., and Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24 March (12) (2006) 2169-2175
8. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 July (7) (1998) 3279-3289
9. Campos-Neto A., Porrozzi R., Greeson K., Coler R.N., Webb J.R., Seiky Y.A., et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 69 June (6) (2001) 4103-4108
10. Goto Y., Bogatzki L.Y., Bertholet S., Coler R.N., and Reed S.G. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25 October (42) (2007) 7450-7458
11. Pourshafie M., Morand S., Virion A., Rakotomanga M., Dupuy C., and Loiseau P.M. Cloning of S-adenosyl-l-methionine:C-24-Delta-sterol-methyltransferase (ERG6) from Leishmania donovani and characterization of mRNAs in wild-type and amphotericin B-resistant promastigotes. Antimicrob Agents Chemother 48 July (7) (2004) 2409-2414
12. Belkaid Y., Von Stebut E., Mendez S., Lira R., Caler E., Bertholet S., et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168 April (8) (2002) 3992-4000
13. Coler R.N., Goto Y., Bogatzki L., Raman V., and Reed S.G. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD(4+) T cells. Infect Immun 75 September (9) (2007) 4648-4654
14. Goto Y., Sanjoba C., Asada M., Saeki K., Onodera T., and Matsumoto Y. Adhesion of MRP8/14 to amastigotes in skin lesions of Leishmania major-infected mice. Exp Parasitol 119 May (1) (2008) 80-86
15. Belkaid Y., Mendez S., Lira R., Kadambi N., Milon G., and Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 165 July (2) (2000) 969-977
16. Anderson C.F., Mendez S., and Sacks D.L. Nonhealing infection despite Th1 polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol 174 March (5) (2005) 2934-2941
17. Tonui W.K., Mejia J.S., Hochberg L., Mbow M.L., Ryan J.R., Chan A.S., et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 72 October (10) (2004) 5654-5661
18. Tonui W.K., and Titus R.G. Cross-protection against Leishmania donovani but not L. braziliensis caused by vaccination with L. major soluble promastigote exogenous antigens in BALB/c mice. Am J Trop Med Hyg 76 March (3) (2007) 579-584
19. Rafati S., Kariminia A., Seyde-Eslami S., Narimani M., Taheri T., and Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon gamma producing CD8(+) T lymphocyte activation. Vaccine 20 June (19-20) (2002) 2439-2447
20. Al-Wabel M.A., Tonui W.K., Cui L., Martin S.K., and Titus R.G. Protection of susceptible BALB/c mice from challenge with Leishmania major by nucleoside hydrolase, a soluble exo-antigen of Leishmania. Am J Trop Med Hyg 77 December (6) (2007) 1060-1065
21. Gamboa-Leon R., Paraguai de Souza E., Borja-Cabrera G.P., Santos F.N., Myashiro L.M., Pinheiro R.O., et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani. Vaccine 24 May (22) (2006) 4863-4873
22. Coler R.N., Skeiky Y.A., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 August (8) (2002) 4215-4225
23. Titus R.G., Sherry B., and Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 170 December (6) (1989) 2097-2104
24. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 147 November (9) (1991) 3149-3155
25. Titus R.G., Kelso A., and Louis J.A. Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon. Clin Exp Immunol 55 January (1) (1984) 157-165
26. Liew F.Y., Parkinson C., Millott S., Severn A., and Carrier M. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69 April (4) (1990) 570-573
27. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 July (7) (2007) 843-850
28. Liew F.Y., Li Y., and Millott S. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 145 December (12) (1990) 4306-4310
29. Sadick M.D., Heinzel F.P., Holaday B.J., Pu R.T., Dawkins R.S., and Locksley R.M. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J Exp Med 171 January (1) (1990) 115-127
30. Tobin J.F., Reiner S.L., Hatam F., Zheng S., Leptak C.L., Wirth D.F., et al. Transfected Leishmania expressing biologically active IFN-gamma. J Immunol 150 June (11) (1993) 5059-5069
31. Himmelrich H., Launois P., Maillard I., Biedermann T., Tacchini-Cottier F., Locksley R.M., et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 164 May (9) (2000) 4819-4825
32. Miles S.A., Conrad S.M., Alves R.G., Jeronimo S.M., and Mosser D.M. A role for IgG immune complexes during infection with the intracellular pathogen Leishmania. J Exp Med 201 March (5) (2005) 747-754
33. Kane M.M., and Mosser D.M. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 166 January (2) (2001) 1141-1147